2014

Acquisition of Ebix, Inc. by an affiliate of Goldman, Sachs & Co. May Not Be in the Best Interests of Ebix Shareholders

SAN DIEGO and ATLANTA, May 2, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Ebix, Inc. (NASDAQ: EBIX) by Goldman, Sachs & Co. On May 1, 2013, Ebix announced that it had entered into a definitive merger agreement whereby Ebix shareholders will receive $20.00 in cash for each share.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

The Board of Directors' Actions May Prevent Ebix Shareholders from Receiving Maximum Value for Their Stock

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Ebix is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger or whether they are seeking to benefit themselves.

The $20.00 merger consideration represents a premium of only 7.47% based on Ebix's closing price on April 30, 2013, the last trading day prior to the merger announcement.  The 7.4% premium is substantially below the median premium of 35.47% for comparable transactions over the past three years.  Further, the $20.00 offer price is substantially below the target price of $25.00 set by an analyst at BOE Securities on September 13, 2012, and a target price of $24.00 set by an analyst at Craig-Hallum on March 13, 2013. 

Is the Acquisition Best for Ebix and Its Shareholders?

On March 14, 2013, Ebix released its 2012 financial results reflecting record revenue growth.  Specifically, Ebix reported fourth quarter revenue of $54.0 million an increase of 22.6% as compared to the same quarter 2011.  Further, Ebix reported full year revenue increased to $199.4, an 18% increase over 2011.  Moreover, earnings per share for the fourth quarter 2012 increased 9%, to $0.48 per share.  In announcing these results, Robin Raina, Ebix's Chairman, President, and CEO, stated, "The Company's 2012 results reflect the strength of Ebix's core business that helped us deliver outstanding results in one of the most challenging years for the insurance industry in a decade.  Our revenue, operating cash flow, liquidity and diluted EPS were all at record levels as we look forward to continued high levels of performance in 2013."

Given these facts, the firm is examining the board of directors' decision to sell Ebix now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects.   

Ebix shareholders have the option to file a class action lawsuit to secure the best possible price for shareholders and the disclosure of material information so shareholders can vote on the transaction in an informed manner.  Ebix shareholders interested in information about their rights and potential remedies can contact Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/ebix-inc/

Attorney Advertising.Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
ddonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP



RELATED LINKS
http://www.robbinsarroyo.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.